al-Katib A - Search Results

1

Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines.

Aref A, Mohammad R, Yudelev M, Choudhuri R, Strowbridge A, Orton C, al-Katib A. Aref A, et al. Radiat Oncol Investig. 1999;7(3):158-62. doi: 10.1002/(SICI)1520-6823(1999)7:3<158::AID-ROI4>3.0.CO;2-B. Radiat Oncol Investig. 1999. PMID: 10406057

2

Protein studies of human non-Hodgkin's B-lymphoma: appraisal by two-dimensional gel electrophoresis.

Mohammad RM, Maki A, Vistisen K, al-Katib A. Mohammad RM, et al. Electrophoresis. 1994 Dec;15(12):1566-72. doi: 10.1002/elps.11501501225. Electrophoresis. 1994. PMID: 7720694

3

Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.

Aref A, Narayan S, Tekyi-Mensah S, Varterasian M, Dan M, Eilender D, Karanes C, al-Katib A. Aref A, et al. Radiat Oncol Investig. 1999;7(3):186-91. doi: 10.1002/(SICI)1520-6823(1999)7:3<186::AID-ROI8>3.0.CO;2-2. Radiat Oncol Investig. 1999. PMID: 10406061

4

Neutron and photon clonogenic survival curves of two chemotherapy resistant human intermediate-grade non-Hodgkin lymphoma cell lines.

Aref A, Yudelev M, Mohammad R, Choudhuri R, Orton C, Al-Katib A. Aref A, et al. Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):999-1003. doi: 10.1016/s0360-3016(99)00258-8. Int J Radiat Oncol Biol Phys. 1999. PMID: 10571208

5

Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.

Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O. Mohammad RM, et al. Mol Cancer Ther. 2003 Dec;2(12):1361-8. Mol Cancer Ther. 2003. PMID: 14707277

6

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM. Varterasian ML, et al. J Clin Oncol. 1998 Jan;16(1):56-62. doi: 10.1200/JCO.1998.16.1.56. J Clin Oncol. 1998. PMID: 9440723 Clinical Trial.

7

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Al-Katib AM, et al. Clin Cancer Res. 1998 May;4(5):1305-14. Clin Cancer Res. 1998. PMID: 9607591

8

Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.

Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FW, Wall NR, Al-Katib AM. Mohammad RM, et al. Int J Oncol. 1999 May;14(5):945-50. doi: 10.3892/ijo.14.5.945. Int J Oncol. 1999. PMID: 10200346

9

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM. Varterasian ML, et al. Clin Cancer Res. 2000 Mar;6(3):825-8. Clin Cancer Res. 2000. PMID: 10741703 Clinical Trial.

10

Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.

Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. Nabha SM, et al. Anticancer Drugs. 2000 Jun;11(5):385-92. doi: 10.1097/00001813-200006000-00009. Anticancer Drugs. 2000. PMID: 10912955

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters